Gabelli & Co Investment Advisers’s Pacific Biosciences PACB Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-733,892	Closed	-$2.53M	–	245
2020 Q2	$2.53M	Sell	733,892 -217,057	-23%	-$739K	0.58%	38
2020 Q1	$2.91M	Buy	950,949 +35,825	+4%	+$147K	0.44%	44
2019 Q4	$4.7M	Sell	915,124 -387,267	-30%	-$1.97M	0.54%	40
2019 Q3	$6.72M	Sell	1,302,391 -9,816	-0.7%	-$54.9K	0.76%	36
2019 Q2	$7.94M	Buy	1,312,207 +103,093	+9%	+$723K	0.85%	29
2019 Q1	$8.74M	Buy	1,209,114 +720,064	+147%	+$5.21M	1.12%	22
2018 Q4	$3.62M	Buy	+489,050	New	+$3.1M	0.51%	41

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Gabelli & Co Investment Advisers's PACB Position: Q3 2020 in Review

Gabelli & Co Investment Advisers sold out of Pacific Biosciences (PACB) in Q3 2020, closing a stake of 733,892 shares — an estimated $2.53M sold.

Gabelli & Co Investment Advisers first reported a position in PACB in Q4 2018 and held it in 7 quarters. The position peaked at $8.74M in Q1 2019. 174 funds tracked by Wall St. Rank hold PACB as of Q3 2020.

Gabelli & Co Investment Advisers reported no remaining Pacific Biosciences position as of Q3 2020 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 733,892 Pacific Biosciences shares in Q3 2020, an estimated $2.53M.
Gabelli & Co Investment Advisers first reported a position in Pacific Biosciences in Q4 2018 and held it in 7 quarters.
Gabelli & Co Investment Advisers's Pacific Biosciences position peaked at $8.74M in Q1 2019.
174 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2020.

Based on Gabelli & Co Investment Advisers's 13F filing for Q3 2020, filed 6 Nov 2020.